Refine by
Transformational Science And Technology Articles & Analysis
88 news found
CD Genomics, a leading provider of genomic research solutions, today announced the launch of its cutting-edge Nanopore sequencing services, marking a significant advancement in DNA and RNA analysis capabilities. This innovative technology, developed by Oxford Nanopore Technologies, is set to transform the landscape of life ...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced European CE Mark approval of the AlphaVac F1885 System for the non-surgical removal of thrombi or emboli from the pulmonary arteries and for ...
These innovative products are set to revolutionize the field of materials science and open up new possibilities for engineers and researchers around the world. ...
"Completion of this important strategic acquisition enables us to deliver best-in-class data and system interoperability services to the healthcare and life sciences sectors powered by AvantAI® and our high-density compute capabilities," said Tim Lantz, Chief Executive Officer of Avant Technologies. ...
Synaptive Medical Inc., a global med tech and technology company solving surgical, imaging and data challenges, is proud to announce the appointment of Chris Marrus as Chief Commercial Officer. This appointment underscores Synaptive’s commitment to driving sales, expanding its market presence, and advancing innovative solutions in imaging and surgical technology focused on combining the ...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). APEX-AV is a ...
Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced a new partnership with Perigon Pharmacy 360, a full-service, specialty digital pharmacy, to enhance accessibility, affordability and adherence for patients treating symptoms of ADHD with Tris’ ...
CD Genomics, a prominent leader in the genomics and transcriptomics arena, proudly unveils its latest innovation, the Degradome Sequencing service. This technology promises to revolutionize the field of transcriptomics research, offering researchers an unprecedented window into RNA degradation patterns and elevating our comprehension of gene regulation and expression. RNA degradation is a ...
Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain, addiction and neurological disorders, today announced that Health Canada has authorized the use of Quillivant® ER (extended release) for the treatment of attention deficit hyperactivity disorder (ADHD) in children ages 6 to 12. Quillivant ER will be available as both an oral ...
Positive results confirm findings from prior studies evaluating the abuse potential of cebranopadol, further highlighting its potential as a safe and potent alternative to traditional opioids Registrational phase 3 clinical trials of cebranopadol in moderate to severe acute pain are on track to initiate in Q4 2023 – Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage ...
Englese earned his Bachelor of Science in Marketing from Villanova University and his Master of Business Administration in Finance from Pennsylvania State University. ...
Breukelman is a pioneer in imaging technology, initially as principal and chairman of IMAX Corporation, followed by significant transformative contributions to medical and scientific research companies in information technology and strategic development. ...
This acquisition of Cellesce affirms Molecular Devices’ commitment to investing in 3D biology technologies that transform the drug discovery process and drive development of novel therapeutics. ...
Portal Instruments is pleased to announce the appointment of Dr. Veena Rao, PhD, as Chief Business Officer, effective December 5th, 2022. Dr. Rao will lead the identification, evaluation, and negotiation of partnership opportunities for Portal. In addition, Dr. Rao, in close collaboration with the CEO and cross-functional team, will guide the company’s short and long-term commercial ...
Clinicians at Ardent’s BSA Hospital in Amarillo, Texas, began using the BioButton wearable device and BioCloud analytics engine in September to automate the collection of inpatient vital signs in general care units and increase both patient and clinician satisfaction. With plans for expansion across Ardent’s 30 hospitals, the program also leverages BioIntelliSense’s FDA-cleared ...
BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885) announced today that it has officially submitted the Phase 3 clinical trial protocol for BRM421 in the treatment of dry eye disease (DED) to the U.S. Food and Drug Administration (FDA). If the FDA has no further comments after the 30-day review period, BRIM will proceed to initiate the Phase 3 clinical trial in December. Based on its ...
Key Takeaways: Next-generation single-molecule protein sequencing technology is poised to transform the science and research community’s understanding of the proteome by unlocking unprecedented insights about the human body - just as the advent of next-generation DNA sequencing has revolutionized our knowledge of the human genome over ...
Anavasi Diagnostics ('Anavasi'), a medical technology company focused on the development of novel molecular diagnostic testing, recently announced the addition of a Chief Financial Officer, Chief Operating Officer and Chief Commercial Officer to its management roster. ...
Mammoth Biosciences, a biotech company harnessing next-generation CRISPR technology to detect and cure disease, has been chosen by Endpoints News Editor John Carroll as one of the most promising biotech startups for this year’s Endpoints 11 annual special report. ...
HINGHAM, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that it will be presenting the Company’s Self-Cleaning Shunt (SCS) at the 16th Asian Australasian Congress of Neurological Surgeons (AACNS). The AACNS is hosted by the Israel Neurosurgery Society and is being held from September 6th – 8th in Jerusalem, Israel. Dr Gustavo Rajz, Head of ...